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Abstract
The incidence of bovine tuberculosis (bTB) in the GB has been increasing since the 1980s.
Immunisation, alongside current control measures, has been proposed as a sustainable
measure to control bTB. Immunisation withMycobacterium bovis bacillus Calmette-Guerin
(BCG) has been shown to protect against bTB. Furthermore, much experimental data indi-
cates that pulmonary local immunity is important for protection against respiratory infections
includingMycobacterium tuberculosis and that pulmonary immunisation is highly effective.
Here, we evaluated protection againstM. bovis, the main causative agent of bTB, conferred
by BCG delivered subcutaneously, endobronchially or by the new strategy of simultaneous
immunisation by both routes. We also tested simultaneous subcutaneous immunisation
with BCG and endobronchial delivery of a recombinant type 5 adenovirus expressing myco-
bacterial antigen 85A. There was significantly reduced visible pathology in animals receiv-
ing the simultaneous BCG/BCG or BCG/Ad85 treatment compared to naïve controls.
Furthermore, there were significantly fewer advanced microscopic granulomata in animals
receiving BCG/Ad85A compared to naive controls. Thus, combining local and systemic
immunisation limits the development of pathology, which in turn could decrease bTB
transmission.
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Introduction
Infection withMycobacterium bovis, the principal agent responsible for bovine tuberculosis
(bTB), in the GB cattle herd is an increasing challenge to the GB farming industry. This
increase is due in part to the existence of a wildlife reservoir and it has implications for both
animal and human health and welfare [1]. Immunisation of cattle has been proposed for con-
trol of bTB as it is thought that the current test and slaughter policy alone will not be sufficient
for eradication of the disease, in the presence of a wildlife reservoir [2].
BCG is a live attenuated strain ofM. bovis that has been used as a vaccine against TB in
humans since 1921 [3]. It was isolated by Calmette and Guérin in the early 1900s from a case
of bTB mastitis and it has been used experimentally as a vaccine in cattle. The protection
afforded by BCG has been shown to be variable in both humans and cattle [4, 5]. Furthermore,
immunisation with BCG interferes with the current diagnostic assay for bTB and its use in the
field is prohibited by both domestic and European legislation. Nevertheless, experimentally,
BCG is the standard by which all other vaccines are judged.
A human serotype 5, replication deficient adenovirus (Ad) expressing the mycobacterial
mycolyl transferase antigen Ag85A (Ad85A) [6] has been developed as a vaccine againstM.
tuberculosis (Mtb). In mice Ad85A is protective against pulmonaryMtb challenge when
administered intranasally (i.n.) but not parenterally. Similarly after parenteral BCG priming a
single i.n. but not parenteral booster immunisation with Ad85A induced improved protection
against airwayMtb challenge compared to parenteral BCG only [7–10]
Heterologous prime-boost immunisation with parenteral BCG followed by boosting with
parenteral Ad85A has also been tested in cattle and compared with BCG alone; fewer BCG
primed Ad85A boosted animals presented with visible lesions after infection withM. bovis and
the pathology score was reduced [11]. More recently we have shown that endonbronchial
boosting of BCG vaccinated cattle with Ad85A induces immune responses similar to those
induced by Ad85A [12].
Recently, it has been shown that simultaneous immunisation of mice with subcutaneous (s.
c.) and i.n. BCG (SIM BCG/BCG) or BCG s.c. and recombinant antigen 85A protein (r85A) i.
n., increased protection over BCG given by either route alone [13]. Protection was shown not
to be due to a prime-boost effect but to inhibition of early growth ofMtb in the lung as a result
of i.n. immunisation [14].
The experiments described here are aimed at determining whether SIM BCG/BCG or SIM
BCG/Ad85A are more protective than parenteral or endobronchial delivery of BCG in cattle.
Materials and Methods
Cattle
The study protocol was approved by the APHA Animal Use Ethics Committee (UK Home
Office PCD number 70/6905) and performed in accordance with the UK Animal (Scientific
Procedures) Act 1986. Male, weaned, 5–7 months old Holstein-Friesian calves were purchased
from farms known to be free of bTB. Forty nine animals were randomly divided into four
groups of ten and one of nine and inoculated as described below.
Vaccination and infection
M. bovis BCG Danish 1331 (Staten Serum Institute, Copenhagen, Denmark) was used for vac-
cination and was prepared as per manufacturer’s instructions (SSI, Denmark). The Ad85A
construct encoding for antigen 85A has been previously described [10].
The five groups of cattle were vaccinated as follows:
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Group one was inoculated with 106 cfu of BCG s.c.; group two with 106 cfu of BCG e.b.;
group three simultaneously with 5 X 105 cfu of BCG s.c. and 5 X 105 cfu of BCG SSI e.b. (SIM
BCG/BCG); group four simultaneously with 106 cfu of BCG SSI s.c. and 2 x 109 pfu Ad85A e.b.
(SIM BCG/Ad85A); group five, nine animals, naïve controls, were left unimmunised.
Animals were infected twelve weeks later with 2 X 103 cfuM. bovis AF2122/97 e.b. as previ-
ously described [15]
Evaluation of immune responses
Immune responses were evaluated through the production of IFNγ using ELISA or ex vivo ELI-
Spot as described below.
ELISA was used to measure secretion of IFN in whole blood as previously described [16–
18]; triplicate samples were incubated overnight at 37°C with medium alone (negative control
[NC]),M. bovis PPD (PPD-B) (10 μg/ml) (VLA-Weybridge, UK), Rv0288, also known as
TB10.4 (10 μg/ml) (Proteix, Prague, Czech Republic), r85A protein (10 μg/ml) (Lionex, Ger-
many) or pokeweed mitogen (PWM) Sigma-Aldrich, UK) (5 μg/ml) in an atmosphere of 5%
CO2 and 95% humidity. After overnight incubation, blood was centrifuged at 300 x g for 10
min. Plasma was harvested and stored at –80°C until use. Concentration of IFN was deter-
mined using the Bovigam™ assay (Prionics AG, Switzerland); results were first corrected for
background by subtracting unstimulated values and then expressed as mean optical density at
450 nm (O.D.) +/- standard error of the mean.
Ex vivo ELISpot was used to determine the frequency of IFNγ producing cells; duplicate
samples of bovine PBMC at 1 x 106 /ml were incubated overnight at 37°C with the same panel
of antigens as was used for the whole blood assay in an atmosphere of 5% CO2 and 95% humid-
ity using 96-well flat membrane-bottomed plates (Immobilon-P polyvinylidene difluoride
membranes; Millipore, Ireland). Plates were coated and developed with antibodies to bovine
IFNγ provided in a commercially available kit (Mabtech, Stockholm, Sweden); in accordance
with the manufacturer’s instructions [19]. Results were corrected for background by subtract-
ing unstimulated values and adjusted to express numbers of precursors per million cells.
Gross (visible) pathology and histopathology
Twenty four weeks after BCG vaccination, cattle were euthanized and detailed post mortem
examinations (PME) carried out as described elsewhere [20]; briefly, personnel performing
postmortems were blind to the vaccination status of the animals examined. Lungs were exam-
ined externally for the occurrence of lesions, followed by slicing of the lung into 0.5- to 1-cm-
thick slices that were then individually examined for lesions. In addition, lymph nodes of the
head and pulmonary regions were removed, weighed and sliced into 1 to 2 mm thick sections
and examined for the presence of visible lesions. Pathology scores were assigned for lungs as
follows: 0 = no visible lesions; 1 = no visible lesions but lesions apparent on slicing; 2 =< 5 visi-
ble lesions of<10 mm in diameter; 3 =>6 visible lesions of<10 mm in diameter or a single
distinct visible lesion of>10 mm in diameter; 4 =>1 distinct visible lesion of>10 mm in
diameter; 5 = visible coalescing lesions. Individual lobe scores for each animal were added up
to calculate the lung score. For lymph nodes the following criteria were applied: 0 = no necrosis
or visible lesions; 1 = small focus (1 to 2 mm in diameter); 2 = several small foci or necrotic
area of at least 5 by 5 mm; 3 = extensive necrosis. Individual lymph node scores were added up
to calculate the lymph node score. Lung and lymph node scores were added to obtain the total
pathology score for individual animal. Tissue samples were preserved in 10% phosphate buff-
ered formalin and used for evaluation of histopathology as previously described [21]. For histo-
pathology, sections of thoracic (caudal mediastinal, cranial mediastinal, cranial
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tracheobronchial, left and right bronchial) lymph nodes were used. Tissue sections were
stained with haematoxilin and eosin for examination with light microscopy to assess the num-
ber, developmental stage and distribution of each granuloma (I-IV) as previously described
[21, 22]. The pathologist reading the slides was blind to the distribution of the animals within
the groups.
Evaluation of bacterial load
Tissue samples collected at PME were homogenized in sterile water using a stomacher (Seward,
U.K.). Viable counts were performed on serial dilutions of the macerate in PBS. Suspensions
were plated on 7H10 agar plates containing sodium pyruvate (4.16 mg/ml) and 10% (vol/vol)
Middlebrook oleic acid-albumin-dextrose-catalase enrichment. Plates were seeded with 500, 50
and 5 μl of macerate; therefore, the limit of detection is 2 cfu/ml. Counts were performed in
preselected sections with visible lesions. However, when no lesions were found tissue samples
were taken to determine possible presence of mycobacteria in the absence of lesions. Data are
presented in S1 Table.
Statistical analysis
Statistical analysis and graph drawing were carried out using GraphPad’s Instat 3 and Prism v
6.0 (GraphPad Software, CA. USA). Immune responses between groups were analysed using a
Kruskal-Wallis test with Dunn’s multiple column post-test comparison. Immune response
kinetics were analysed using a Friedman test with Dunn’s multiple column post-test compari-
son. For comparison of visible pathology and histopathology the non-parametric two tail
Mann-Whitney test was used. Significance is indicated by one symbol p<0.05, on the graph;
two symbols p<0.01; and three symbols p<0.001.
Results
Immune responses
Fig 1 shows the antigen specific immune responses induced by different vaccination regimes,
as determined by measurement of IFNγ with the Bovigam assay, following overnight culture of
whole blood with mycobacterial antigens. Levels of PPD-B-induced IFNγ produced after BCG
s.c., rose from week three onwards. At week 6 and 12, responses to PPD-B induced by BCG/
Ad85A were higher than the responses observed in N.C. (ρ<0.05). In terms of kinetics, BCG s.
c. induced responses to PPD-B at weeks 3 and 6 that were significantly different to those
detected at week 0 (ρ<0.05); BCG/BCG and BCG/Ad85A also had responses to PPD-B at week
6 that were significantly different to those detected prior to vaccination at week 0 (ρ<0.05) (S1
Fig). Negligible levels of IFNγ were detected in naive control animals before challenge with
bTB.
Twelve weeks after vaccination animals were infected withM. bovis. At week 14, only ani-
mals vaccinated with BCG e.b. showed a statistically different response to PPD-B compared to
N.C. animals (ρ<0.05). In terms of kinetics, only animals vaccinated with BCG s.c. or BCG e.b
showed responses to PPD-B at week 14 (ρ<0.05) and ρ<0.01, respectively). At week 16, the
responses to PPD-B and Rv0288 detected in animals in the N.C. group were significantly differ-
ent from the responses detected in animals vaccinated with BCG s.c. (ρ<0.05). Also at week 16,
there were differences in the responses of animals in the N.C. group to r85 compared to
responses in BCG/BCG vaccinated animals (ρ<0.05). Animals in all groups made responses to
PPD-B from week 16 until the end of the experiment that were larger than those detected at
week 0 (range of ρ<0.05, ρ<0.01, ρ<0.001). SIM BCG/Ad85 vaccinated showed responses to
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Fig 1. Different vaccination regimes induced different responses to mycobacterial antigens.
Determination of the secretion of IFNγ by whole blood cells, measured by ELISA, from animals vaccinated
with BCG at week 0 and challenged withM. bovis at week 12; vaccination and challenge are indicated by
arrows on the x axis. Group average of antigen-specific whole blood IFNγ secretion, expressed as OD
450nm, was corrected for background and evaluated at the weeks indicated on the x axis. Animal groups are
indicated naïve controls (N.C.) (open rhomboid); SIM BCG/Ad85A (inverted open triangle); BCG e.b. (open
SIM Vaccination of Cattle against TB
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Rv0288 from week 16 until the end of the experiment that were larger than those detected at
week 0 in the same animals (ρ<0.05 and ρ<0.01). At week 14, N.C. animal showed responses
to Rv0288 that were larger than those observed at week 0 in the same group ρ<0.01).
Fig 2 shows the frequency of IFNγ producing cells after vaccination and infection. None of
the vaccination regimes induced responses to any of the antigens used greater than those
observed in the non-vaccinated group, however animals vaccinated with BCG s.c. (ρ<0.001),
SIM BCG/BCG (ρ<0.01) and SIM BCG/Ad85 (ρ<0.01) showed responses that were higher
than those observed at week 0 (S2 Fig). After infection, as after vaccination, no differences were
observed in the responses to mycobacteria antigens between the different treatment groups but
BCG s.c. vaccinated animals showed responses to Rv0288 that were different to those observed
at week 0 (ρ<0.05). At week 19, N.C. animals (ρ<0.05) and those vaccinated with BCG e.b.
(ρ<0.01) or SIM BCG/Ad85 (ρ<0.05) showed responses to PPD-B that were different from
those observed at week 0. Responses to PPD-B detectable at week 23 in BCG e.b. and SIM
BCG/BCG vaccinated animals were different to those detected at week 0 (ρ<0.05).
Pathological analysis
Fig 3 summarises the pathological findings in all five groups of animals 24 weeks after the ini-
tial vaccination, i.e. 12 weeks after infection. Fig 3A shows the total pathology scores of lungs
and respiratory tract associated lymph nodes, for each experimental group. The group with the
largest number of animals showing no visible lessions was SIM BCG/Ad85 with 6/10 animals
showing no visible lessions; followed by animals in the SIM BCG/BCG and BCG e.b. groups
with 5/10 in each. In BCG s.c. vaccinated animals 2/10 animals showed no visible lesions and
in naïve controls only 1/10 infected animals showed no visible lesions. This assessment of visi-
ble pathology indicates that SIM BCG/BCG and SIM BCG/Ad85A animals had significantly
lower pathology scores than naïve controls (ρ<0.05). There was a trend for all the vaccinated
groups to have reduced pathology compared with naïve controls but the difference was not sig-
nificant when comparing animals from BCG s.c. and BCG e.b. groups to naïve.
Fig 3B shows the outcome of histopathological evaluation of the different stages of granu-
loma formation in thoracic lymph nodes [21]. We consider granulomata type III and IV as
advancing granulomata in which the host is unable to control the infection; comparison of the
sum of type III and IV granulomata in the different groups showed that only SIM BCG/Ad85A
animals had significantly lower number of these granulomata compared to naïve controls
(ρ<0.05).
Discussion
Intradermal Ad85A enhances protection againstM. bovis infection in cattle when used in a het-
erologous prime-boost regime with subcutaneous BCG [11]. Similarly, Ad85A administered i.
n. to guinea pigs or mice enhances the protective effect of BCG against pulmonaryMtb, in both
species more effectively than intradermal or intramuscular boosting [7, 10]. In mice, immuni-
sation directly into the lung primes local memory immune responses and is effective because
local immune responses can inhibit the early phase ofMtb growth, while intradermal or subcu-
taneous immunisation inhibitsMtb growth only later after infection [14]. These effects are
triangle); BCG s.c. (open square); SIM BCG/BCG (open circle). Error bars represent the standard error of the
mean (SEM). Data were analysed using a using a Kruskal-Wallis test with Dunn’s multiple column post-test
comparison. Statistical significance is indicated as follows: * difference between BCG/Ad85A and N.C.; ^
indicates differences between BCG e.b. and N.C.; % indicates differences between BCG s.c. and N.C.; &
indicates differences between BCG/BCG and N.C. One symbol indicates ρ<0.05.
doi:10.1371/journal.pone.0142270.g001
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Fig 2. The comparative frequency of IFNγ secreting cells responding to mycobacterial antigens does
not appear to be affected by different vaccination regimes. The frequency of IFNγ producers in PBMC, as
determined by ELISpot, from animals immunised with BCG at week 0 and challenged with 2000 cfuM. bovis
at week 12 was determined as indicated in materials and methods; immunisation and challenge are indicated
by arrows on the x axis. IFNγ ELISpot was evaluated at the weeks indicated on the x axis, corrected for
SIM Vaccination of Cattle against TB
PLOSONE | DOI:10.1371/journal.pone.0142270 November 6, 2015 7 / 12
additive and not a result of prime-boosting of the immune system, since the systemic and pul-
monary vaccines can be unrelated antigenically and can be administered simultaneously [13].
Both SIM BCG/BCG and SIM BCG/r85A, increased protection compared to parenteral BCG
immunisation alone [13].
Here we show that vaccination of cattle with SIM BCG/BCG or SIM BCG/Ad85 confers a
degree of significantly enhanced protection against challenge withM. bovis. Of interest, only
animals in the SIM BCG/Ad85A showed statistically significant differences in the number of
type III and IV granuloma compared to naïve controls and this group was also had the highest
number of animals with no visible lesions after infection.
Whilst the SIM BCG/BCG and SIM BCG/Ad85A animals did not show a statistically signifi-
cant difference from the BCG s.c. or e.b. immunised cattle, these two groups were the only ones
to show a statistically significant difference from the naïve group. In terms of numbers of type
III and IV granulomata, which we consider to indicate that the host is unable to contain the
growth of mycobacteria, only the SIM BCG/Ad85A group showed a statistically significant dif-
ference from the naïve group. These observations are reminiscent of the improved protection
against TB found in mice immunised simultaneously with BCG/r85A [13] and suggests that e.
b. mucosal immunisation induces local responses that may contribute to the control ofM.
bovis by the host and a reduction in pathology, compared to the other immunisation regimes.
It is of interest that the number of animals presenting no visible lesions did not match the num-
ber of animals harbouring mycobacteria (please see S1 Table) i.e. animals with no visible
lesions or granulomas were positive for mycobacterial growth (due to the discreet nature and
uneven distribution of lesions in bovine TB it is not possible to present biologically meaningful
quantitative data; hence data are presented in a qualitative form).
The patterns of responses measured by the Bovigam™ and IFNγ ELISPOT varied between
the different groups but it is not possible to state that one immunization regime induced stron-
ger or weaker IFNγ responses to PPD-B than another. These data confirm that evaluation of
IFNγ on its own is not a correlate of protection and highlights the need for the development of
correlates of protection against tuberculosis.
In this occasion, the level of protection conferred by BCG s.c. compared to naïve controls
was not significant and perhaps this is a reflection of the variability of protection conferred by
BCG in an outbred species. Although not statistically significantly different, nevertheless, it is
of interest that in a head to head comparison, BCG e.b. is at least as effective as BCG s.c. at
reducing the severity of disease in terms of visible pathology and histopathology. Further stud-
ies are needed to examine whether pulmonary administration of BCG is more efficient in pro-
tecting against bTb infection and transmission. Furthermore, since in cattle parenteral prime
boosting with Ad85A is effective [11], while in mice and guinea pigs pulmonary boosting is
greatly superior [7, 10] it will be interesting to further investigate the mechanism(s) of protec-
tion afforded by local vaccination with Ad85A in cattle.
From a practical immunisation standpoint, it will be important to determine whether muco-
sal is more effective than parenteral boosting in cattle and whether simultaneous immunisa-
tion, which has the advantage that it can be performed at one time, is more effective than
heterologous prime boosting approaches. Finally, although mice are protected for several
background and expressed as spot forming units (SFU) per 106/PBMC. No significant differences in the
frequency of IFNγ secreting cells responding to PPD-B, Rv0288 or r85A was detected between the different
vaccination regimes after vaccination or after infection. N.C. (open rhomboid); SIM BCG/Ad85A inverted
triangle; SIM BCG/BCG (open triangle); BCG e.b. (open square); BCG s.c. (open circle). Error bars represent
the standard error of the mean (SEM). Data were analysed using a using a Kruskal-Wallis test with Dunn’s
multiple column post-test comparison.
doi:10.1371/journal.pone.0142270.g002
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Fig 3. Evaluation of pathology for each group of treated cattle. Treatment groups are indicated on the x axis. Summary of total visible pathology scores
for each group evaluated as previously described [20] (A). Summary of the number of granulomata at different developmental stages for each experimental
group in thoracic lymph node samples isolated at post-mortem fromM. bovis infected animals. Granulomata were classified as previously described [21];
vertically hatched boxes; stage I granulomata, open boxes; stage II granulomata, dotted boxes; stage III granulomata, black boxes; stage IV granulomata
(B). Bar spanning groups BCG/BCG and N.C. indicates statistically significant difference between these two groups; Bar spanning groups BCG/Ad85A and
N.C. indicates statistically significant difference between these two groups the indicated groups; * indicates ρ<0.05.
doi:10.1371/journal.pone.0142270.g003
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months by Ad85A [14], the duration of protection induced by prime boosting or simultaneous
immunisation with BCG s.c. and Ad85A given by the pulmonary route, remains to be deter-
mined. Clearly if SIM or parenteral/mucosal prime boost regimes are shown to be more effec-
tive than purely parenteral regimes, safe, practical and effective means for immunising the
lungs will be required for field implementation.
Supporting Information
S1 Fig. Subcutaneous inoculation with BCG induces responses to PPD-B. Determination of
the secretion of IFNγ by whole blood cells, measured by ELISA, from animals vaccinated with
BCG at week 0 and challenged withM. bovis at week 12; vaccination and challenge are indi-
cated by arrows on the x axis. Group average of antigen-specific whole blood IFNγ secretion,
expressed as OD 450nm, was corrected for background and evaluated at the weeks indicated
on the x axis. Responses to PPD-B (closed circles) Rv0288 (open triangles) and r85A (open dia-
monds) are indicated at the same time points. Each graph represents the responses to the dif-
ferent antigens of animals in each group: A: BCG s.c., B: BCG e.b., C: SIM BCG/BCG, D: SIM
BCG/Ad85A and E: naïve controls. Error bars represent the standard error of the mean (SEM).
Data were analysed using a Friedman test with Dunn’s multiple column post-test comparison
Statistical significance is indicated by  for PPD-B; ^ for Rv0288.  = ρ<0.001;  or ^^, =
ρ<0.01;  or ^ = ρ<0.05.
(EPS)
S2 Fig. Subcutaneous vaccination with BCG induces PPD-B specific IFNγ secretors. The
frequency of IFNγ secreting cells in response to PPD-B (closed circles) Rv0288 (open triangles)
and r85A (open rhomboid) are shown at the indicated time points. Each graph represents the
responses to the different antigens of animals in the different groups: BCG s.c., BCG e.b., SIM
BCG/BCG, SIM BCG/Ad85A and naïve controls (A-E, respectively). Error bars represent the
standard error of the mean (SEM). Data were analysed using a Friedman test with Dunn’s mul-
tiple column post-test comparison. Statistical significance is indicated by  for PPD-B; ^ for
r85A; and + for Rv0288. , ^^^ or +++ = ρ<0.001; , ^^, ++ = ρ<0.01; , ^ or + = ρ<0.05.
(EPS)
S1 File. GraphPad Prism 6 file containing readings for average O.D.450 nm readings of
Bovigam Elisa performed with supernatants of whole blood cultures that had been stimu-
lated as indicated in materials and methods.
(PZFX)
S2 File. GraphPad Prism 6 file containing data derived from ELISPOT experiments. Elispot
counts obtained after multiplication of original data by 5 to obtain spot forming units/106
PBMC. Cultures were set up with 1x106 PBMC/well in a final volume of 200 μl with stimulating
antigen as indicated in materials and methods.
(PZFX)
S3 File. GraphPad Prism 6 file containing total pathology scores for individual animals
and granulomata counts per group as determined by histopathology. Pathology score and
granulomata counts are presented in Fig 3A and 3B respectively.
(PZF)
S4 File. Excel file containing pathology scores for individual animals divided into lung and
lymph nodes. Total gross pathology counts for each animal in the different groups in the dif-
ferent tissues evaluated as indicated in materials and methods.
(XLSX)
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S1 Table. Bacterial load in the individual tissues of animals in the different treatment
groups evaluated at postmortem as described in materials and methods. + indicates pres-
ence ofM. bovis. - indicates no mycobacteria were recovered from these tissues.
(XLSX)
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